Submitted to FDA for review, but not approved in the US or EU in Novo Nordisk's cited materials.
Open related pageCalculator safety
cagrisema calculator
This CagriSema calculator does not calculate doses, units, injections, or conversion from semaglutide. CagriSema is not approved in the US or EU in Novo Nordisk's current public materials.
Direct answer
CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide and semaglutide. Novo Nordisk filed for FDA approval in December 2025 and said an FDA decision was expected in 2026.
FDA says cagrilintide cannot be used in compounding under federal law.
Open related pageSemaglutide and tirzepatide products require clinician-supervised prescribing.
Open related pageWhat to know before acting on this search
- Novo Nordisk describes CagriSema as a combination of a long-acting amylin analogue and semaglutide.
- FDA review is not the same as approval.
- Cagrilintide and retatrutide cannot be used in compounding under federal law, according to FDA.
- Semaglutide's approved label does not make CagriSema an approved product.
Safety and compliance notes
- Do not use CagriSema calculators to copy trial dosing or combine separate products.
- Do not treat compounded cagrilintide, research-use cagrilintide, or research-use CagriSema claims as approved care.
- Combination products can have safety and tolerability considerations that require regulator and clinician review.
Safer next step
Track official Novo Nordisk and FDA status, and discuss currently approved options with a qualified healthcare provider.
Medical disclaimer
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. FDA-approved medicines such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.